Bryan Johnson wakes up at 4:30 AM, eats his last meal before noon, and goes to bed at 8:30 PM. He hasn’t had an unplanned meal in years. Every bite of food is measured. He takes somewhere between 50 and 100 pills daily depending on which version of his protocol you’re reading. A team of over 30 doctors monitors his body across 70+ organ systems with MRI scans, ultrasounds, colonoscopies, DEXA scans, and blood panels so frequent that he checked his own veins by ultrasound to make sure the serial draws weren’t damaging them. They weren’t.
He does all of this because he wants to not die. Not metaphorically. He sells a supplement brand called “Don’t Die.” He is the subject of a Netflix documentary called Don’t Die: The Man Who Wants to Live Forever. He’s given a talk about wanting to live until 2140, which is the year of the last Bitcoin halving, a detail that tells you everything you need to know about where Bryan Johnson is coming from philosophically.
He sold Braintree to PayPal for $800 million in 2013. He is now 47. He has the penis of a man decades younger, according to the nocturnal erection data he has publicly shared. The internet does not know quite what to do with him.
The question worth asking isn’t whether Bryan Johnson is extreme — obviously he is — but whether any of what he’s doing is actually instructive, and if so, which parts.
The $2 million number is misleading
The headline figure always gets reported the same way: Bryan Johnson spends $2 million a year on his anti-aging protocol. That framing implies the supplements and treatments cost $2 million, which creates the impression that his results, whatever they are, require $2 million to access.
Johnson has addressed this directly. Most of the money goes to measurement. The MRI scans, the specialist consultations, the ultrasounds, the comprehensive blood panels every few months, the advanced imaging for cancer screening, the colonoscopies, the hyperbaric oxygen chamber sessions — that’s where the budget lives. The food, sleep, and exercise protocols are structurally free. The supplement stack is expensive by normal standards but not by anything approaching $2 million.
He’s said this plainly: the majority of people can afford the actual protocol. The measurements are what cost. This matters because the entire conversation about Blueprint tends to collapse into “only rich people can do this,” which is partly wrong in an important way.
What the research actually supports
There’s a real distinction between the different tiers of Blueprint, and most coverage ignores it completely.
The bedrock — sleep, diet, and exercise. Johnson sleeps 8 hours on a fixed schedule, gets morning light, keeps his bedroom at 65–68°F, and cuts screens an hour before bed. He eats around 2,250 calories daily, heavily plant-based, with at least 100 grams of protein, substantial fiber, and olive oil at every meal. He exercises roughly 6 hours a week — a mix of Zone 2 cardio, HIIT, and resistance training. These aren’t biohacks. They’re the most replicated interventions in longevity science, supported by decades of large-cohort research. Regular exercise reduces all-cause mortality by 30–40% in meta-analyses. Sleep quality and consistency have robust associations with cognitive health and lifespan. The Mediterranean-style dietary pattern has the best human evidence base of any diet for cardiovascular and metabolic outcomes.
If Johnson’s protocol were only these three things, his biological markers would probably still be impressive. This is the part nobody wants to talk about because it’s not exotic.
Evidence-grounded supplements. The supplement tier that has real science behind it is shorter than the full stack but not nothing. Vitamin D, especially for deficient individuals, has solid validation for bone health and immune function. Omega-3s have consistent cardiovascular and anti-inflammatory evidence. Creatine has a strong case not just for muscle but for cognitive function. NAC supports glutathione production and has genuine antioxidant evidence. Magnesium’s roles in sleep, muscle function, and hundreds of enzymatic reactions are well established. Cocoa flavanols had a large cardiovascular trial, the COSMOS study, that showed meaningful benefits. Extra virgin olive oil has some of the best epidemiological and mechanistic evidence of any food for longevity outcomes.
These aren’t particularly dramatic items. They’re achievable for $55–90 a month if you shop reasonably.
Prescription drugs with promising but incomplete evidence. Metformin is interesting. It’s a diabetes drug that activates AMPK, a pathway associated with the benefits of caloric restriction, and it extends lifespan in multiple animal models. The TAME trial (Targeting Aging with Metformin) is currently running to test whether it meaningfully delays age-related disease in non-diabetic humans. Results aren’t in yet. Johnson takes 2,000mg daily — a significant dose that carries real side effects and absolutely requires medical supervision. It’s a reasonable bet for someone doing this under physician monitoring. It’s not something to self-prescribe based on a podcast.
Acarbose, which blunts blood sugar spikes after meals, has also extended lifespan in mice and is part of Blueprint. Again: promising data, no completed human longevity trials, prescription-only, and not for casual self-experimentation.
The rapamycin chapter. For years, rapamycin was the centerpiece of the more experimental tier of Blueprint. It’s an mTOR inhibitor originally developed as an immunosuppressant and has the strongest longevity data of any drug in animals — a landmark 2009 Nature paper showed it extended median lifespan in mice even when started late in life. Johnson used it for nearly five years at various doses and schedules. Then he stopped.
The reasons were: intermittent infections, elevated resting heart rate, metabolic shifts. His conclusion was that the side effects outweighed the benefits, at least at the doses he was using. This is worth sitting with. Johnson is someone with 30 doctors monitoring him constantly, running blood panels frequently enough to catch problems early, and optimizing based on real data. He still got burned by rapamycin. The interaction effects between rapamycin, metformin, acarbose, caloric restriction, and the rest of his protocol are complex enough that his own team couldn’t cleanly identify which element caused the problems. The lesson isn’t that rapamycin is useless — the longevity data in animals is too good to dismiss — but that stacking multiple mTOR-suppressing interventions without careful dose titration is genuinely risky in ways that weren’t obvious upfront.
The noise. Young blood plasma from his teenage son. Gene therapy trials. Hyperbaric oxygen sessions. Full-body LED panels. Electromagnetic stimulation of his lower abdomen. These exist in the protocol. The plasma exchange was inspired by parabiosis research in mice. None of these have convincing human longevity evidence. Johnson frames them explicitly as research bets, not recommendations. That framing is honest. But the distinction gets lost when these elements get reported alongside the well-grounded ones, which is how Blueprint ends up looking like a tabloid story instead of a serious experiment.
The biological age claims: real, but overstated
Johnson’s reported biological age numbers are the part of Blueprint that gets both the most attention and the most misrepresentation.
He uses an epigenetic clock called DunedinPACE, developed by researchers at Duke and the University of Otago studying a longitudinal cohort in Dunedin, New Zealand. DunedinPACE is a third-generation clock — it doesn’t estimate how old you look on paper, it estimates how fast you’re aging right now based on DNA methylation patterns. Johnson’s DunedinPACE score of around 0.66 means he’s aging roughly 0.66 years for every calendar year that passes. That’s genuinely unusual and better than the population average.
The “31 years of age reversal” claim is where things get shaky. Morgan Levine, the researcher who developed PhenoAge and one of the leading figures in epigenetic clock science, pointed this out publicly: you can’t apply a rate of aging to your total lifespan and get a meaningful “years reversed” number. The math Johnson uses multiplies his aging rate (0.66) by his age (47) to get 31 — but that’s not what the clock measures or what the number means. It more accurately suggests he’s slowed his pace of aging relative to average, which is still meaningful and still remarkable. It’s not “I have the body of a 16-year-old.”
The deeper issue is that even the best epigenetic clocks have meaningful test-retest variability — the same person getting two tests close together can show different results. At the population level, these clocks predict morbidity and mortality well. At the individual level, each data point carries more noise than the popular coverage suggests. Johnson’s averages across multiple measurements are more reliable than any single reading, but the confidence intervals around individual claims should be wider than his content implies.
The signal under the noise
Here’s what’s genuinely instructive about Blueprint, separate from the specific interventions.
Johnson’s core methodology is: measure first, then act. His philosophy isn’t “take everything that might work.” It’s “test your baseline, identify what’s out of range, intervene specifically, and measure whether it worked.” He’s dropped interventions that his data didn’t support — including rapamycin, which he’d believed in for years. He’s adjusted doses based on biomarker response rather than sticking to a protocol for consistency’s sake.
Matt Kaeberlein, a longevity researcher at the University of Washington, has articulated the key limitation of Johnson’s experiment: when someone changes their diet, fixes their sleep, starts exercising seriously, and takes 100 supplements simultaneously, you genuinely cannot identify which of those things is doing the work. There’s no control. This is not a clinical trial; it’s an n-of-1 experiment with no way to isolate variables. Johnson knows this and says so. But it means his results, however real, can’t be cleanly attributed to any specific intervention.
What can be separated is the evidence quality of the components themselves. And when you do that exercise, the answer is clear: the free stuff is doing most of the heavy lifting. Sleep. Caloric moderation. Plant-heavy, nutrient-dense diet. Consistent exercise across multiple modalities. These aren’t interesting to write about. They’re not brandable. They won’t get you on a Netflix documentary.
But the longevity science is unambiguous: a 50-year-old who sleeps 8 hours, exercises 6 hours a week, eats whole foods at a modest caloric intake, and doesn’t drink alcohol will outperform on biological aging metrics compared to a 50-year-old taking NMN, rapamycin, and 80 other supplements while sleeping 6 hours and skipping cardio. No version of an expensive supplement stack compensates for the fundamentals. Johnson does the fundamentals better than almost anyone alive, and then stacks expensive experiments on top.
The instructive part is the methodology, not the pill list. The idea that your health decisions should be driven by data rather than intuition or marketing; that you should measure your baseline before supplementing; that you should test whether something actually moved your numbers rather than assuming it did. A comprehensive blood panel costs a fraction of what most people spend annually on supplements they’re taking without knowing whether their levels warranted supplementation in the first place.
What to actually take away from this
The version of Blueprint most people can access and benefit from is not very extreme. Get 7–8 hours of sleep on a consistent schedule. Eat mostly whole foods, substantially plant-based, with protein and healthy fats, and control total calories. Exercise 5–6 hours a week including both cardio and resistance training. Don’t drink. Get a blood panel and supplement based on what’s actually deficient or suboptimal rather than what’s trending on X.
That’s roughly 85–90% of what Johnson’s results are probably attributable to, based on the evidence. The rest is research bets, some of which will pan out and some of which — as the rapamycin chapter demonstrated — will backfire even under expert supervision.
The $2 million experiment is useful to the broader field partly because Johnson publishes everything, including his mistakes. Longevity science has a long history of high-profile interventions that looked promising and didn’t hold up: mega-dose vitamin C, human growth hormone for healthy adults, testosterone therapy without indication. Some elements of Blueprint’s experimental tier may eventually join that list. Some may become standard recommendations in 20 years.
What probably won’t end up on either list: sleep, exercise, and a decent diet. Those have been there the whole time, accessible to anyone, and consistently outperforming everything else in the research. Bryan Johnson is, among other things, a very vivid demonstration of that.
Sources:
- Johnson, B. Blueprint Protocol. protocol.bryanjohnson.com (updated April 2026)
- Belsky, D.W. et al. (2022). DunedinPACE, a DNA methylation biomarker of the pace of aging. eLife. PMC8853656.
- Levine, M. (2024). Public commentary on DunedinPACE calculation methodology. via Twitter/X, September 2024.
- Kaeberlein, M. Quoted in GeneEditing101 Blueprint Protocol analysis, February 2026.
- Szyf, M. Quoted in Wikipedia: Bryan Johnson (accessed April 2026).
- Harrison, D.E. et al. (2009). Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature, 460, 392–395.
- Healthspan Clinical Analysis. Analyzing Bryan Johnson’s Rapamycin Pivot. gethealthspan.com, 2024.
- FormBlends Medical Team. Bryan Johnson’s Blueprint Protocol in 2026: What Changed and What It Costs. April 2026.
- Prova Track. Bryan Johnson’s Blueprint Protocol: What’s Proven and What’s Speculative. December 2025.
- Apsley, A. et al. (2025). From Population Science to the Clinic? Limits of Epigenetic Clocks as Personal Biomarkers. Epigenomics. PMC12714307.
- Willett, W.C. et al. (2018). Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. New England Journal of Medicine.
- Pedisic, Z. et al. (2020). Is there a dose-response relationship of physical activity and mortality? British Journal of Sports Medicine.
Leave a Reply